Rate My Professor Pratima Chowdary

Her research specializations encompass strategies for personalised haemophilia management, clinical outcomes improvement, biomarkers for joint disease, and novel assays for bleeding diathesis and thrombotic tendency. She has acted as chief investigator for numerous academic and commercial clinical trials, including gene therapy and novel treatments for severe haemophilia, and oversaw the development of a biobank at the Royal Free Hospital. Professor Chowdary has authored over 100 peer-reviewed publications and three textbook chapters. Notable works include 'Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B' in the New England Journal of Medicine (2022), 'Haemophilia' in The Lancet (2025), and 'Bioengineered Factor VIII — More Innovation for Hemophilia A' editorial in the New England Journal of Medicine (2024). She has chaired working parties, data safety monitoring boards, and trial steering committees, and served as a panel member for the National Institute for Health Research Health Technology Assessment Programme in the UK and Norway, contributing significantly to advancements in haemostasis and haemophilia treatment.